COMPANY:

Biomark Diagnostics

"BioMark Diagnostics Inc...announce that its latest work, has been published in Cancers, titled Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms. This paper sheds light on the metabolic alterations that define pulmonary neuroendocrine neoplasms (NENs), focusing on identifying specific metabolomic biomarkers for early diagnosis and monitoring."

"BioMark Diagnostics Inc...announce that its latest work, has been published in Cancers, titled Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms.This paper sheds light on the metabolic alterations that define pulmonary neuroendocrine neoplasms (NENs), focusing on identifying specific metabolomic biomarkers for early diagnosis and monitoring."

"BioMark Diagnostics Inc...today the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ). Over 5,400 patient samples were analyzed using BioMark’s innovative lung cancer assay, demonstrating the test’s potential to revolutionize early detection and improve patient outcomes."

"BioMark Diagnostics Inc...announce today that long time collaborators at the University of Manitoba Therapeutics will be presenting this week compelling new research findings on glioblastoma at the 2024 Globalization of Pharmaceutics Education Network (GPEN) Conference in Copenhagen from July 14-17, 2024."

"BioMark Diagnostics Inc...and Rubix LS...jointly announce today the signature of a strategic partnership to develop better diagnostic tools to enhance lung cancer screening and improve breast cancer screening program, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), by focusing on reaching underserved communities. This collaboration combines the innovative strengths of both organizations to develop accessible, non-invasive, and accurate diagnostic solutions that promise to set new standards in early detection and personalized cancer treatment."

"BioMark Diagnostics Inc...announce that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023."

"BioMark Diagnostics Inc...announce...that its abstract has been accepted for poster presentation at the upcoming San Antonio Brest Cancer Symposium (SABCS) taking place December 5-9, 2023 in San Antonio, Texas...Our study identified and validated a simple, high-performing, metabolite-based test for the early detection of BC. These findings could provide the foundations for the development of a routine blood-based test for women at the highest risk for BC that is cost-effective, accurate, and reliable."

"BioMark Diagnostics Inc...announce that the Japan Patent Office (JPO) has issued Divisional Patent Application N°7311659 titled 'Methods of detecting lung cancer' using urine biomarkers. The issued patent belongs to a larger family of patents on the Company’s biomarker panel for detecting lung cancer."

"BioMark Diagnostics Inc...announce that its latest leading-edge research was presented during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting...The poster entitled 'Large retrospective validation study of metabolomic biomarkers for resectable lung cancer detection and risk assessment', was presented by senior author, Dr Andrew Maksymiuk, during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session on June 3, 2023, from 8:00 – 11:00 a.m. CT at the McCormick Place in Chicago."

"BioMark Diagnostics Inc...announce today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,656,229 which was filed as a provisional on June 26, 2015 and titled Method of Detecting Lung Cancer. The issued patent belongs to a larger family of patents on the Company’s biomarker panel for detecting lung cancer, and complements similar patents already approved in Japan and Canada and pending in Europe, and China."

"BioMark Diagnostics Inc...is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer detection and monitoring of lung cancer...As clinical trial success relies on effective patient recruitment, BioMark is delighted to announced today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year."

"BioMark Diagnostics Inc...announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing and measuring treatment response for various forms of hard to detect and treat cancer. The technology can also be used as a surveillance tool for recurring disease. BioMark is currently pursuing two clinical trials using this liquid biopsy platform that can improve identification and assessing response to treatment for patients with lung cancer and glioblastoma."

"BioMark Diagnostics will work with the Icahn School of Medicine at Mount Sinai in New York to develop early-stage lung cancer diagnostics, BioMark said on Tuesday...Vancouver, Canada-based BioMark is developing a multiomic liquid biopsy assay for the early detection and screening of lung cancer, and will take part in clinical studies with Icahn Mount Sinai to study at-risk populations with its plasma biomarkers and machine-learning tools...The partners also aim to develop a test for determining lung cancer subtype and stage using circulating tumor cells and metabolomics."